Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: john jansen who wrote (692)	6/23/1999 1:02:00 AM
From: Marty	Read Replies (2) \| Respond to of 705

John, if you would check out the stuff that has been published on their website you'd find answers to a lot of your questions. The following is from a February release: " This double-blind, placebo-controlled Phase 2b trial is designed to study the effects of three doses of NEOTROFIN(TM) over the course of 90 days of treatment in as many as 400 patients with mild to moderate Alzheimer's disease. NEOTROFIN(TM) is believed to exert its effects through a mechanism different from other Alzheimer's disease drugs currently available. The efficacy measures to be employed in this study were selected to detect the types of cognitive and behavioral changes which may occur in patients with Alzheimer's disease. "Because of the positive results from our recent U.S. Phase 2a study demonstrating statistically significant changes in certain endpoint parameters in patients with Alzheimer's disease, we are greatly encouraged to accelerate our development plans," said Michelle S. Glasky, Ph.D., Vice President, Scientific Affairs of Neotherapeutics. "By expanding the testing of NEOTROFIN(TM) internationally, we have the opportunity to enroll patients more rapidly and to expand the regulatory process required for marketing approval into additional technically developed countries." And in March: "IRVINE, Calif., March 15 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news, NEOTW - news) today announced a global expansion of its human clinical trials testing the efficacy of NEOTROFIN(TM) (AIT-082, leteprinim potassium), the Company's lead compound for the treatment of Alzheimer's disease. In February, NeoTherapeutics announced that it received approval in South Africa and today the Company is announcing additional regulatory approvals that will allow the expansion of this trial to Canada and Australia. In this double-blind placebo controlled trial, clinicians will study the effects of three dose levels of NEOTROFIN(TM) for 90 days of treatment in approximately 400 patients with mild to moderate Alzheimer's disease. ''We are pleased with the positive clinical results obtained to date in our phase 1 and phase 2 North American studies with NEOTROFIN(TM). Now we are accelerating the development of this compound for Alzheimer's disease by increasing the number of clinical sites and the number of patients involved through this global expansion,'' said Michelle S. Glasky, Ph.D., Vice President, Scientific Affairs of NeoTherapeutics. Dr. Glasky continued, ''The recent results from our U.S. Phase 2a study have demonstrated that NEOTROFIN(TM) can induce behavioral and cognitive improvement in patients with Alzheimer's disease after only one month of treatment.'' =========================================== You can get this information as easy as I can from their web site at neotherapeutics.com I wish the site was more complete and had more current information on it but at least it has the press releases.